Achivements

2024

  1. Abuduyimiti T, Goto H, Kimura K, Oshima Y, Tanida R, Kamoshita K, Leerach N, Abuduwaili H, Oo HK, Li Q, Galicia-Medina CM, Takayama H, Ishii KA, Nakano Y, Takeshita Y, Iba T, Naito H, Honda M, Harada K, Yamamoto Y, Takamura T. Diabetes accelerates steatohepatitis in mice: liver pathology and single-cell gene expression signatures. Am J Pathol 2024 in press.
  2. Sugita H, Nakanuma S, Munesue S, Ishikawa T, Tokoro T, Takei R, Okazaki M, Kato K, Takada S, Makino I, Ozaki N, Yamamoto Y, Yagi S. Cilostazol improves the prognosis after hepatectomy in rats with sinusoidal obstruction syndrome. J Gastroenterol Hepatol 2024 in press.

2023

  1. Higuchi T, Takeuchi A, Munesue S, Yamamoto N, Hayashi K, Harashima A, Yamamoto Y, Tsuchiya H. A nonsteroidal anti-inflammatory drug, zaltoprofen, inhibits the growth of extraskeletal chondrosarcoma cells by inducing PPARγ, p21, p27, and p53. Cell Cycle 2023 in press.
  2. Inaba Y, Hashiuchi E, Watanabe H, Kimura K, Oshima Y, Tsuchiya K, Murai S, Takahashi C, Matsumoto M, Kitajima S, Yamamoto Y, Honda M, Asahara S, Ravnskjaer K, Horike S, Kaneko S, Kasuga M, Nakano H, Harada K, Inoue H. ATF3 switches cell death from apoptosis to necroptosis in hepatic steatosis. Nat Commun 2023 in press.
  3. Matsumoto T, Suzuki T, Nakamura M, Yamamoto M, Iizuka T, Ono M, Kagami K, Kasama H, Kanda T, Sakai Y, Iwadare J, Matsuoka A, Kayahashi K, Wakae K, Muramatsu M, Kyo S, Yamamoto Y, Mizumoto Y, Daikoku T, Fujiwara H. Androgen promotes squamous differentiation of atypical cells in cervical intraepithelial neoplasia via an ELF3-dependent pathway. Cancer Med 2023 in press.
  4. Watanabe H, Kubo M, Taniguchi A, Asano Y, Hiramatsu-Asano S, Ohashi K, Zeggar S, Katsuyama E, Katsuyama T, Sunahori-Watanabe K, Sada KE, Matsumoto Y, Yamamoto Y, Yamamoto H, Son M, Wada J. Amelioration of nephritis in receptor for advanced glycation end-products (RAGE)-deficient lupus-prone mice through neutrophil extracellular traps. Clin Immunol 2023 in press.
  5. Hattori T, Cherepanov SM, Sakaga R, Roboon J, Nguyen DT, Ishii H, Takarada-Iemata M, Nishiuchi T, Kannon T, Hosomichi K, Tajima A, Yamamoto Y, Okamoto H, Sugawara A, Higashida H, Hori O. Postnatal expression of CD38 in astrocytes regulates synapse formation and adult social memory. EMBO J 2023 in press.
  6. Kitaoka S, Tomohiro A, Ukeshima S, Liu K, Wake H, Kimura SH, Yamamoto Y, Nishibori M, Furuyashiki T. Repeated social defeat stress induces HMGB1 nuclear export in prefrontal neurons, leading to social avoidance in mice. Cells 2023 in press.
  7. Oshima Y, Yamamoto Y. Life events and oxytocin -recent topics-. Glycative Stress Res 2023 in press.
  8. Yonekura H, Kato I, Yamamoto Y, Ikeda T, Higashida H, Okamoto H. Biosynthesis and function of VIP and oxytocin: mechanisms of C-terminal amidation, oxytocin secretion and transport. Endocrinology 2023 in press.
  9. Hara S, Ohta K, Aono D, Tamai T, Kurachi M, Sugimori K, Mihara H, Ichimura H, Yamamoto Y, Nomura H. Feasibility and reliability of the pandemic-adapted online-onsite hybrid graduation OSCE in Japan. Adv Health Sci Educ Theory Pract 2023 in press.
  10. Saeki M, Munesue S, Higashi Y, Harashima A, Takei R, Takada S, Nakanuma S, Ohta T, Yagi S, Tajima H, Yamamoto Y. Assaying ADAMTS13 activity as a potential prognostic biomarker for sinusoidal obstruction syndrome in mice. Int J Mol Sci 2023; 24: 16328.
  11. Ye D, Miyoshi A, Ushitani T, Kadoya M, Igeta M, Konishi K, Shoji T, Yasuda K, Kitaoka S, Yagi H, Kuroda E, Yamamoto Y, Cheng J, Koyama H. RAGE in circulating immune cells is fundamental for hippocampal inflammation and cognitive decline in a mouse model of latent chronic inflammation. Brain Behav Immun 2023 in press.
  12. Takahashi N, Yokoi S, Kimura H, Naiki H, Matsusaka T, Yamamoto Y, Nakatani K, Kasuno K, Iwano M. Renoprotective effects of extracellular fibroblast specific protein 1 via nuclear factor erythroid 2-related factor-mediated antioxidant activity. Sci Rep 2023 in press.

2022

  1. Yamamoto Y, Harashima A, Munesue S, Higashida H. Use of cocultures to measure the blood-brain barrier permeability of oxytocin. Methods Mol Biol 2022; 2384: 247-255.
  2. Miyagawa T, Iwata Y, Oshima M, Ogura H, Sato K, Nakagawa S, Yamamura Y, Kamikawa Y, Miyake T, Kitajima S, Toyama T, Hara A, Sakai N, Shimizu M, Furuichi K, Munesue S, Yamamoto Y, Kaneko S, Wada T. Soluble receptor for advanced glycation end products protects from ischemia- and reperfusion-induced acute kidney injury. Biol Open 2022; 11(1): bio058852.
  3. Oshima Y, Harashima A, Munesue S, Kimura K, Leerach N, Goto H, Tanaka M, Niimura A, Hayashi K, Yamamoto H, Higashida H, Yamamoto Y. Dual nature of RAGE in host reaction and nurturing the mother-infant bond. Int J Mol Sci 2022; 23(4): 2086.
  4. Yamazaki H, Tajima H, Yamamoto Y, Munesue S, Okazaki M, Ohbatake Y, Nakanuma S, Makino I, Miyashita T, Takamura H, Ohta T. Thrombopoietin accumulation in hepatocytes induces a decrease in its serum levels in a sinusoidal obstruction syndrome model. Mol Med Rep 2022; 25(6): 201.
  5. Yamamoto H, Yamamoto Y. Evolution and diabetic vasculopathy. J Diabetes Investig 2022; 13(7): 1111-1113.
  6. Hayashi K, Sato K, Ochi S, Kawano S, Munesue S, Harashima A, Kimura K, Oshima Y, Kyoi T, Yamamoto Y. Inhibitory effects of Saururus chinensis extract on RAGE-dependent inflammation and diabetes-induced dysregulation of vasodilation. Int J Mol Sci 2022; 23(10): 5757.
  7. Shirasaki T, Yamagoe S, Shimakami T, Murai K, Imamura R, Ishii KA, Takayama H, Matsumoto Y, Tajima-Shirasaki N, Nagata N, Shimizu R, Yamanaka S, Abe A, Omura H, Kawaguchi K, Okada H, Yamashita T, Yoshikawa T, Takimoto K, Taharaguchi M, Takatsuka S, Miyazaki Y, Tamai T, Tanabe Y, Kurachi M, Yamamoto Y, Kaneko S, Matsumoto K, Takamura T, Honda M. Leukocyte cell-derived chemotaxin 2 is an antiviral regulator acting through the proto-oncogene MET. Nat Commun 2022; 13(1): 3176.
  8. Katagiri T, Espinoza L, Uemori M, Ikeda H, Hosokawa K, Ishiyama K, Yoroidaka T, Imi T, Takamatsu H, Ozawa T, Kishi H, Yamamoto Y, Elbadry IM, Yoshida Y, Chonabayashi K, Takenaka K, Akashi K, Nannya Y, Ogawa S, Nakao S. Hematopoietic stem progenitor cells with malignancy-related gene mutations in patients with acquired aplastic anemia are characterized by the increased expression of CXCR4. eJHaem 2022; 3(3): 669-680.
  9. Higashida H, Gerasimenko M, Yamamoto Y. Receptor for advanced glycation end-products and child neglect in mice: A possible link to postpartum depression. Compr Psychoneuroendocrinol 2022; 11: 100146.
  10. Higashida H, Furuhara K, Lopatina O, Gerasimenko M, Hori O, Hattori T, Hayashi Y, Cherepanov SM, Shabalova AA, Salmina AB, Minami K, Teruko Yuhi T, Tsuji C, Fu PY, Liu Z, Luo S, Zhang A, Yokoyama S, Shuto S, Watanabe M, Fujiwara K, Munesue S, Harashima A, Yamamoto Y. Oxytocin dynamics in the body and brain regulated by the receptor for advanced glycation end-products, cd38, cd157, and nicotinamide riboside. Front Neurosci 2022; 16: 858070.
  11. Aoki T, Kinoshita J, Munesue S, Hamabe-Horiike T, Yamaguchi T, Nakamura Y, Okamoto K, Moriyama H, Nakamura K, Harada S, Yamamoto Y, Inaki N, Fushida S. Hypoxia-induced CD36 expression in gastric cancer cells promotes peritoneal metastasis via fatty acid uptake. Ann Surg Oncol 2022 in press.
  12. Matsumoto T, Iizuka T, Nakamura M, Suzuki T, Yamamoto M, Ono M, Kagami K, Kasama H, Wakae K, Muramatsu M, Horike SI, Kyo S, Yamamoto Y, Mizumoto Y, Daikoku T, Fujiwara H. FOXP4 inhibits squamous differentiation of atypical cells in cervical intraepithelial neoplasia via an ELF3-dependent pathway. Cancer Sci 2022; 113(10): 3376-3389.
  13. Osonoi S, Mizukami H, Takeuchi Y, Sugawa H, Ogasawara S, Takaku S, Sasaki T, Kudoh K, Ito K, Sango K, Nagai R, Yamamoto Y, Daimon M, Yamamoto H, Yagihashi S. RAGE activation in macrophage and development of neuropathy in mice with experimental type 1 diabetes. JCI Insight 2022; 7(23): e160555.

2021

  1. Momeni Z, Bautista M, Neapetung J, Urban R, Yamamoto Y, Krishnan A, Campanucci VA. RAGE signaling is required for AMPA receptor dysfunction in the hippocampus of hyperglycemic mice. Physiol Behav 2021; 229: 113255.
  2. Takata N, Ishii K, Takayama H, Nagashimada M, Kikuchi A, Takeshita Y, Matsumoto Y, Ota T, Yamamoto Y, Yamagoe S, Kaneko S, Takamura T. LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH. Sci Rep 2021; 11(1): 555.
  3. Momeni Z, Neapetung J, Pacholko A, Kiir TAB, Yamamoto Y, Bekar LK, Campanucci VA. Hyperglycemia induces RAGE-dependent hippocampal spatial memory impairments. Physiol Behav 2021; 229: 113287.
  4. Munesue S, Liang MingKun, Harashima A, Zhong J, Furuhara K, Boitsova E, Cherepanov SM, Gerasimenko M, Yuhi T, Yamamoto Y, Higashida H. Transport of oxytocin to the brain after peripheral administration by membrane-bound or soluble forms of receptors for advanced glycation end-products. J Neuroendocrinol 2021; 33(3): e12963.
  5. Nair M, Jagadeeshan S, Katselis G, Luan X, Momeni Z, Chumala P, Tam JS, Yamamoto Y, Ianowski J, Campanucci VA. Lipopolysaccharides induce a RAGE-mediated potentiation of sensory neurons and fluid hypersecretion in the mouse trachea. Sci Rep 2021; 11(1):8336.
  6. Gerasimenko M, Lopatina O, Munesue S, Harashima A, Yokoyama S, Yamamoto Y, Higashida H. Receptor for advanced glycation end-products (RAGE) plays a critical role in retrieval behavior of mother mice at early postpartum. Physiol Behav 2021; 235: 113395.
  7. Ugaji S, Kimura K, Yamamoto Y, Munesue S, Harashima A, Aikawa T, Yoshida Y, Hamada T, Hikichi T, Matsubara H, Tsuchiya H. Pyridoxamine improves diabetes-evoked delayed bone repair in mice. J Transl Sci 2021; 7: 1-6.
  8. Leerach N, Munesue S, Harashima A, Kimura K, Oshima Y, Kawano S, Tanaka M, Niimura A, Sakulsak N, Yamamoto H, Hori O, Yamamoto Y. RAGE signaling antagonist suppresses mouse macrophage foam cell formation. Biochem Biophys Res Commun 2021; 555: 74-80.
  9. Roboon J, Hattori T, Ishii H, Takarada-Iemata M, Nguyen D, Heer C, O'Meally D, Brenner C, Yamamoto Y, Okamoto H, Higashida H, Hori O. Inhibition of CD38 and supplementation of nicotinamide riboside ameliorate lipopolysaccharide-induced microglial and astrocytic neuroinflammation by increasing NAD+. J Neurochem 2021; 158(2): 311-327.
  10. Leerach N, Harashima A, Munesue S, Kimura K, Oshima Y, Goto H, Yamamoto H, Higashida H, Yamamoto Y. Glycation reaction and the role of the receptor for advanced glycation end-products in immunity and social behavior. Glycoconj J 2021; 38(3): 303-310.
  11. Tsubokawa D, Kikuchi T, Lee JM, Kusakabe T, Yamamoto Y, Maruyama H. Venestatin from parasitic helminths interferes with receptor for advanced glycation end products (RAGE)-mediated immune responses to promote larval migration. PLoS Pathog 2021; 17(6): e1009649.
  12. Takei R, Miyashita T, Takada S, Tajima H, Ninomiya I, Takamura H, Fushida S, Harashima A, Munesue S, Yagi S, Inaki N, Ohta T, Yamamoto Y. Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis. Cancer Immunol Immunother 2021 in press.
  13. Cherepanov SM, Gerasimenko M, Yuhi T, Shabalova A, Zhu H, Yokoyama S, Salmina AB, Munesue S, Harashima A, Yamamoto Y, Higashida H. An improved sample extraction method reveals that plasma receptor for advanced glycation end-products (RAGE) modulates circulating free oxytocin in mice. Peptides 2021; 146: 170649.
  14. Uchida C, Mizukami H, Hara Y, Saito T, Umetsu S, Igawa A, Osonoi S, Kudoh K, Yamamoto Y, Yamamoto H, Yagihashi S, Hakamada K. Diabetes in humans activates pancreatic stellate cells via RAGE in pancreatic ductal adenocarcinoma. Int J Mol Sci 2021; 22(21): 11716.

2020

  1. Shimizu Y, Harashima A, Munesue S, Oishi M, Hattori T, Hori O, Kitao Y, Yamamoto H, Leerach N, Nakada M, Yamamoto Y, Hayashi Y. Neuroprotective effects of endogenous secretory receptor for advanced glycation end-products in brain ischemia. Aging Dis 2020; 11(3): 547-558.
  2. Shabalova AA, Liang M, Zhong J, Huang Z, Tsuji C, Shnayder NA, Lopatina O, Salmina AB, Okamoto H, Yamamoto Y, Zhong ZG, Yokoyama S, Higashida H. Oxytocin and CD38 in the paraventricular nucleus play a critical role in mouse paternal aggression. Horm Behav 2020; 120: 104695.
  3. Yamamoto Y, Higashida H. RAGE regulates oxytocin transport into the brain. Commun Biol 2020; 3(1): 70.
  4. Oishi M, Munesue S, Harashima A, Nakada M, Yamamoto Y, Hayashi Y. Aquaporin 1 elicits cell motility and coordinates vascular bed formation by downregulating thrombospondin type-1 domain-containing 7A in glioblastoma. Cancer Med 2020; 9(11): 3904-3917.
  5. Kanou S, Miyashita T, Yamamoto Y, Takada S, Nakura M, Okazaki M, Ohbatake Y, Nakanuma S, Makino I, Tajima H, Takamura H, Fushida S, Ohta T. Prophylactic effect of recombinant human soluble thrombomodulin for hepatic sinusoidal obstruction syndrome model mice. In Vivo 2020; 34(3): 1037-1045.
  6. Yamashima T, Ota T, Mizukoshi E, Nakamura H, Yamamoto Y, Kikuchi M, Yamashita T, Kaneko S. Intake of ω-6 PUFA-rich vegetable oils and risk of lifestyle diseases. Adv Nutr 2020; 11(6): 1489-1509.
  7. Liu L, Killoy KM, Vargas MR, Yamamoto Y, Pehar M. Effects of RAGE inhibition on the progression of the disease in hSOD1(G93A) ALS mice. Pharmacol Res Perspect 2020; 8(4):e00636.
  8. Nakura M, Miyashita T, Yamamoto Y, Takada S, Kanou S, Tajima H, Takamura H, Ohta T. Inhibitory effects of beraprost sodium in murine hepatic sinusoidal obstruction syndrome. Anticancer Res 2020; 40(9):5171-5180.
  9. Takaso Y, Noda M, Hattori T, Roboon J, Hatano M, Sugimoto H, Brenner C, Yamamoto Y, Okamoto H, Higashida H, Ito M, Yoshizaki T, Hori O. Deletion of CD38 and supplementation of NAD+ attenuate axon degeneration in a mouse facial nerve axotomy model. Sci Rep 2020; 10(1): 17795.
  10. Oshima Y, Yamamoto Y. RAGE is a transporter of oxytocin, a chemical messenger that affects social behaviors. IMARS Highlights 2020; 15(4): 5-7.
  11. Gerasimenko M, Lopatina O, Shabalova AA, Cherepanov SM, Salmina AB, Yokoyama S, Goto H, Okamoto H, Yamamoto Y, Ishihara K, Higashida H. Distinct physical condition and social behavior phenotypes of CD157 and CD38 knockout mice during aging. PloS ONE 2020; 15(12): e0244022.

2019

  1. Kawano S, Yamamoto Y. Tuning inflammation: inducing ectodomain shedding of receptor for advanced glycation end-products (RAGE) and formation of soluble RAGE. IMARS Highlights 2019; 14(1): 18-19.
  2. Yamamoto Y, Liang M, Munesue S, Deguchi K, Harashima A, Furuhara K, Yuhi T, Zhong J, Akther S, Goto H, Eguchi Y, Kitao Y, Hori O, Shiraishi Y, Ozaki N, Shimizu Y, Kamide T, Yoshikawa A, Hayashi Y, Nakada M, Lopatina O, Gerasimenko M, Komleva Y, Malinovskaya N, Salmina AB, Asano M, Nishimori K, Shoelson SE, Yamamoto H, Higashida H. Vascular RAGE transports oxytocin into the brain to elicit its maternal bonding behaviour in mice. Commun Biol 2019; 2: 76.
  3. Miyoshi A, Koyama S, Sasagawa-Monden M, Kadoya M, Konishi K, Shoji T, Inaba M, Yamamoto Y, Koyama H. JNK and ATF4 as two important platforms for tumor necrosis factor-α-stimulated shedding of receptor for advanced glycation endproducts. FASEB J 2019; 33(3): 3575-3589.
  4. Takamatsu H, Yamamoto K, Tomonobu N, Murata H, Inoue Y, Yamauchi A, Sumardika W, Youyi C, Kinoshita R, Yamamura M, Fujiwara H, Mitsui Y, Araki K, Futami J, Saito K, Iioka H, Ruma MW, Putranto EW, Nishibori M, Kondo E, Yamamoto Y, Toyooka S, Sakaguchi M. Extracellular S100A11 plays a critical role in spread of the fibroblast population in pancreatic cancers. Oncol Res 2019; 27(6): 713-727.
  5. Ichinose W, Cherepanov SM, Shabalova AA, Yokoyama S, Yuhi T, Yamaguchi H, Watanabe A, Yamamoto Y, Okamoto H, Horike S, Terakawa J, Daikoku T, Watanabe M, Mano N, Higashida H, Shuto S. Development of a highly potent analogue and a long-acting analogue of oxytocin for the treatment of social impairment-like behaviors. J Med Chem 2019; 62(7): 3297-3310.
  6. Mitsui Y, Tomonobu N, Watanabe M, Kinoshita R, Sumardika W, Youyi C, Murata H, Yamamoto KI, Sadahira T, Rodrigo AGH, Takamatsu H, Araki K, Yamauchi A, Yamamura M, Fujiwara H, Inoue Y, Futami J, Saito K, Iioka H, Kondo E, Nishibori M, Toyooka S, Yamamoto Y, Nasu Y, Sakaguchi M. Upregulation of mobility in pancreatic cancer cells by secreted S100A11 through activation of surrounding fibroblasts. Oncol Res 2019; 27(8): 945-956.
  7. Hosokawa K, Mizumaki H, Elbadry M, Saito C, Espinoza JL, An DTT, Katagiri T, Harashima A, Kikuchi A, Kanai A, Matsui H, Inaba T, Taniwaki M, Yamamoto Y, Nakao S. Clonal hematopoiesis by SLIT1-mutated hematopoietic stem cells due to a breakdown of the autocrine loop involving Slit1 in acquired aplastic anemia. Leukemia 2019; 33(11): 2732-2766.
  8. Roboon J, Hattori T, Ishii H, Takarada-Iemata M, Le TM, Shiraishi Y, Ozaki N, Yamamoto Y, Sugawara A, Okamoto H, Higashida H, Kitao Y, Hori O. Deletion of CD38 suppresses glial activation and neuroinflammation in a mouse model of demyelination. Front Cell Neurosci 2019; 13: 258.
  9. Zaimoku R, Miyashita T, Tajima H, Takamura H, Harashima A, Munesue S, Yamamoto Y, Ninomiya I, Fushida S, Harada K. Monitoring of heat shock response and phenotypic changes in hepatocellular carcinoma after heat treatment. Anticancer Res 2019; 39(10): 5393-5401.
  10. Sagara A, Harashima A, Munesue S, Kimura K, Leerach N, Oshima Y, Kinoshita Y, Sakai N, Kaneko S, Wada T, Tsuneyama K, Yamamoto H, Yamamoto Y. Protective role of endogenous secretory RAGE against contact hypersensitivity in mouse ear skin. Glycative Stress Res 2019; 6(4): 270-277
  11. Higashida H, Hashii M, Tanaka Y, Matsukawa S, Higuchi Y, Gabata R, Tsubomoto M, Seishima N, Teramachi M, Kamijima T, Hattori T, Hori O, Tsuji C, Cherepanov S, Shabalova A, Gerasimenko M, Minami K, Yokoyama S, Munesue S, Harashima A, Yamamoto Y, Salmina A, Lopatina O. CD38, CD157 and RAGE as molecular determinants for social behavior. Cells 2019; 9(1): E62

2018

  1. Nelissen T, Bamford RA, Tochitani S, Akkus K, Kudzinskas A, Yokoid K, Usui N, Okamoto H, Yamamoto Y, Burbach PH, Matsuzaki H, Oguro-Ando A. CD38 is required for dendritic organisation in visual cortex and hippocampus. Neuroscience 2018; 372: 114-125.
  2. Lam D, Theaker M, Momeni Z, Yamamoto Y, Jagadeeshan S, Campanucci VA. RAGE-dependent potentiation of TRPV1 currents in sensory neurons exposed to high glucose. PLoS ONE 2018; 13(2): e0193312.
  3. Higuchi T, Takeuchi, A, Munesue S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Inatani H, Shimozaki S, Kato T, Aoki Y, Abe K, Taniguchi Y, Aiba H, Murakami H, Harashima A, Yamamoto Y, Tsuchiya H. Anti-tumor effects of a non-steroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression. Cancer Med 2018; 7(5): 1944-1954.
  4. Akther S, Zhong J, Liang M, Cherepanov SM, Lopatina O, Salmina AB, Tsuji C, Tsuji T, Yamamoto Y, Yokoyama S, Higashida H. CD38 in the nucleus accumbens is critical in paternal behavior in mice. Messenger 2018; 6: 81-84.
  5. Tsuji T, Liang M, Lopatina O, Yuhi T, Tsuji C, Zhong J, Akther S, Zhong J, Nishimura T, Amina S, Liu HX, Hashii M, Furuhara K, Yamamoto Y, Yokoyama S, Higashida H. TRPM2, a new player, in cyclic ADP-ribose/CD38-dependent oxytocin release in the hypothalamus. Messenger 2018; 6: 71-75.
  6. Nomura K, Miyashita T, Yamamoto Y, Munesue S, Harashima A, Takayama H, Fushida S, Ohta T. Citrullinated histone H3: early biomarker of neutrophil extracellular traps in septic liver damage. J Surg Res 2018; 234: 132-138.
  7. Kim MJ, Vargas MR, Harlan BA, Killoy KM, Ball L, Comte-Walters S, Gooz M, Yamamoto Y, Beckman JS, Barbeito L, Pehar M. Nitration and glycation turn mature NGF into a toxic factor for motor neurons: a role for p75NTR and RAGE signaling in ALS. Antioxid Redox Signal 2018; 28(18): 1587-1602.
  8. El-Far A, Munesue S, Harashima A, Sato A, Shindo M, Nakajima S, Inada M, Tanaka M, Takeuchi A, Tsuchiya H, Yamamoto H, Shaheen HME, El-Sayed YS, Kawano S, Tanuma S, Yamamoto Y. In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system. Oncology Lett 2018; 15(4): 4627-4634.
  9. Takada S, Miyashita T, Yamamoto Y, Kanou S, Munesue S, Ohbatake Y, Nakanuma S, Okamoto K, Sakai S, Knoshita J, Makino I, Nakamura K, Tajima H, Takamura H, Ninomiya I, Fushida S, Ohta T. Soluble thrombomodulin attenuates endothelial cell damage in hepatic sinusoidal obstruction syndrome. In Vivo 2018; 32(6): 1409-1417.

2017

  1. Cherepanov S, Yokoyama S, Mizuno A, Ichinose W, Lopatina O, Shabalova A, Salmina A, Yamamoto Y, Okamoto H, Shuto S, Higashida H. Structure-specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, plasma and cerebrospinal fluid oxytocin concentrations in mice. Pharmacology Research & Perspectives 2017; 5(1): e00290.
  2. Aikawa T, Matsubara H, Ugaji S, Shirakawa J, Nagai R, Munesue S, Harashima A, Yamamoto Y, Tsuchiya H. Contribution of methylglyoxal to delayed healing of bone injury in diabetes. Mol Med Rep 2017; 16(1): 402-409
  3. Kwak T, Drews-Elger K, Ergonul A, Miller PC, Braley A, Hwang GH, Zhao D, Besser A, Yamamoto Y, Yamamoto H, El-Ashry D, Slingerland JM, Lippman ME, Hudson BI. Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene 2017; 36(11): 1559-72.
  4. Hattori T, Kaji M, Ishii H, Jureepon R, Takarada-Iemata M, Minh Ta H, Manh Le T, Konno A, Hirai H, Shiraishi Y, Ozaki N, Yamamoto Y, Okamoto H, Yokoyama S, Higashida H, Kitao Y, Hori O. CD38 positively regulates postnatal development of astrocytes cell-autonomously and oligodendrocytes non-cell-autonomously. Glia 2017; 65(6): 974-89.
  5. Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I, Munesue S, Harashima A, Harada S, Yamamoto H, Ohta T. Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancer. Oncology Rep 2017; 37(6): 3341-3350.
  6. Harashima A, Yamamoto Y. Perception of pathogenic bacteria by pattern recognition receptor RAGE in the frontline. IMARS Highlights 2017; 12(2): 5-7.
  7. Higashida H, Furuhara K, Yamauchi AM, Deguchi K, Harashima A, Munesue S, Lopatina O, Gerasimenko M, Salmina AB, Zhang JS, Kodama H, Kuroda H, Tsuji C, Suto S, Yamamoto H, Yamamoto Y. Intestinal transepithelial permeability of oxytocin into the blood is dependent on the receptor for advanced glycation end products in mice. Sci Rep 2017; 7(1): 7883.
  8. Okamoto H, Takasawa S, Yamamoto Y. From insulin synthesis to secretion: alternative splicing of type 2 ryanodine receptor gene is essential for insulin secretion in pancreatic β cells. Int J Biochem Cell Biol 2017; 91(PtB): 176-183.
  9. Cherepanov SM, Akther S, Nishimura T, Shabalova AA, Mizuno A, Ichinose W, Satoshi Shuto S, Yamamoto Y, Yokoyama S, Higashida H. Effects of three lipidated oxytocin analogs on behavioral deficits in CD38 knockout mice. Brain Sci 2017; 7(10): E132.
  10. Munesue S, Yamamoto Y. Targeting RAGE: a viable strategy for cancer prevention and treatment? IMARS Highlights 2017; 12(6): 5-6.

2016

  1. Iwamura M, Yamamoto Y, Kitayama Y, Higuchi K, Fujimura T, Hase T, Yamamoto H. Epidermal expression of receptor for advanced glycation end-products (RAGE) is related to inflammation and apoptosis in human skin. Exp Dermatology 2016; 25(3): 235-7.
  2. Ota C, Ishizawa K, Yamada M, Tando Y, Mei H, Takahashi T, Yamamoto Y, Yamamoto H, Kubo H. The receptor for advanced glycation end-products is associated with apoptosis of alveolar epithelial cells in hyperoxia exposure in vitro and in vivo. Respiratory Invest 2016; 54(2): 98-108.
  3. Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I, Munesue S, Harashima A, Harada S, Yamamoto H, Ohta T. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer 2016; 19(4): 1052-65.
  4. Ichiki T, Koga T, Okuno T, Saeki K, Yamamoto Y, Yamamoto H, Sakaguchi M, Yokomizo T. Modulation of leukotriene B4 receptor 1 signaling by receptor for advanced glycation end products, RAGE. FASEB J 2016; 30(5): 1811-22.
  5. Lee BC, Kim MS, Pae M, Yamamoto Y, Eberlé D, Shimada T, Kamei N, Park HS, Sasorith S, Woo JR, You J, Mosher W, Brady HJM, Shoelson SE, Lee J. Adipose natural killer cells regulate adipose tissue macrophages to promote insulin resistance in obesity. Cell Metab 2016; 23(4): 685-98.
  6. Zhong J, Amina S, Liang M, Akther S, Yuhi T, Nishimura T, Higashida C, Tsuji T, Liu HX, Hashii M, Furuhara K, Yokoyama S, Yamamoto Y, Okamoto H, Zhao YJ, Lee HC, Tominaga M, OLopatina O, Higashida H. Cyclic ADP-ribose and heat regulate oxytocin release via CD38 and TRPM2 in the hypothalamus during social or psychological stress in mice. Front Neurosci 2016; 10: 304.
  7. Ta H, Le T, Ishii H, Takarada-Iemata M, Hattori, T, Hashida K, Yamamoto Y, Mori K, Takahashi R, Kitao Y, Hori O. Atf6α deficiency suppresses microglial activation and ameliorates pathology of experimental autoimmune encephalomyelitis. J Neurochem 2016; 139(6): 1124-37.
  8. Takeuchi A, Yamamoto N, Shirai T, Hayashi K, Miwa S, Munesue S, Yamamoto Y, Tsuchiya H. Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma. BMC Cancer 2016; 16: 442.
  9. Miyashita M, Watanabe T, Ichikawa T, Toriumi K, Horiuchi Y, Kobori A, Kushima I, Hashimoto R, Fukumoto M, Koike S, Ujike H, Arinami T, Tatebayashi Y, Kasai K, Takeda M, Ozaki N, Okazaki Y, Yoshikawa T, Amano N, Washizuka S, Yamamoto H, Miyata T, Itokawa M, Yamamoto Y, Arai M. The regulation of soluble receptor for AGEs contributes to carbonyl stress in schizophrenia. Biochem Biophys Res Commun 2016; 479(3): 447-52.
  10. Abouzed TK, Munesue S, Harashima A, Masuo Y, Kato Y, Kahilo K, Yamamoto H, Yamamoto Y. Preventive effect of salicylate and pyridoxamine on diabetic nephropathy. J Diabetes Res 2016; 2016:1786789.

2015

  1. Chandna AR, Baskaran MN, Chang C, Pennington PR, Mousseau DD, Yamamoto Y, Campanucci VA. RAGE mediates the interactivation of nAChRs in sympathetic neurons during high glucose conditions. Eur J Neurosci 2015; 41(3):341-51.
  2. Inaba Y, Furutani T, Kimura K, Watanabe H, Haga S, Kido Y, Yamamoto Y, Harada K, Kaneko S, Oyadomari S, Ozaki M, Kasuga M, Inoue H. Gadd34 regulates liver regeneration in hepatic steatosis. Hepatology 2015; 61(4): 1343-56.
  3. Waseda K, Miyahara N, Taniguchi A, Kurimoto E, Ikeda G, Koga H, Fujii U, Yamamoto Y, Gelfand EW, Yamamoto H, Tanimoto M, Kanehiro A. Emphysema requires the receptor for advanced glycation end products triggering on structural cells. Am J Respir Cell Mol Biol 2015; 52(4): 482-491.
  4. Taniguchi A, Miyahara N, Waseda K, Kurimoto E, Fuji U, Tanimoto Y, Kataoka M, Yamamoto, Y, Gelfand E, Tanimoto M, Yamamoto H, Kanehiro A. Contrasting Roles for the Receptor for Advanced Glycation End-Products on Structural Cells in Allergic Airway Inflammation versus Airway Hyperresponsiveness. Am J Physiol Lung Cell Mol Physiol 2015; 309(8): L789-800.

2014

  1. Toda M, D'Alessandro-Gabazza CN, Takagi T, Chelakkot-Govindalayathila AL, Taguchi O, Roeen Z, Munesue S, Yamamoto Y, Yamamoto H, Gabazza EC, Morser J. Thrombomodulin modulates dendritic cells via both antagonism of high mobility group protein B1 and an independent mechanism. Allergology Int 2014; 63(1):57-66.
  2. Kuretani A, Kawamura R, Munesue S, Yamamoto Y, Honda J, Yamamoto H. Maltitol endows foods with lower 3-deoxyglucosone content and less RAGE agonism as a sweetener against sucrose. Glycative Stress Res 2014; 1(2):25-31.
  3. Okuma Y, Liu K, Wake H, Liu R, Nishimura Y, Hui Z, Teshigawara K, Haruma J, Yamamoto Y, Yamamoto H, Date I, Takahashi HK, Mori S, Nishibori M. Glycyrrhizin inhibits traumatic brain injury in rats by reducing HMGB1-RAGE interaction. Neuropharmacology 2014; 85:18-26.
  4. Motoyoshi S, Yamamoto Y, Munesue S, Igawa H, Harashima A, Saito H, Han H, Watanabe T, Sato H, Yamamoto H. cAMP ameliorates inflammation in macrophages by modulation of receptor for advanced glycation end-products. Biochem J 2014; 463(1): 75-82.
  5. Anisuzzaman, Hatta T, Miyoshi T, Mtsubayashi M, Islam MK, Alim MA, Anas MA, Hasan MM, Matsumoto Y, Yamamoto Y, Yamamoto H, Fujisaki K, Tsuji N. Longistatin secreted with tick saliva blocks RAGE. J Clin Invest 2014; 124(10):4429-44.
  6. Chen X, Zhang L, Zhang IY, Liang J, Wang H, Ouyang M, Wu S, da Fonseca ACC, Weng L, Yamamoto Y, Yamamoto H, Natarajan R, Badie B. Expression of RAGE by tumor macrophages promotes angiogenesis in gliomas. Cancer Res 2014; 74(24):7285-97.
  7. Sakai S, Tajima H, Miyashita T, Nakanuma SI, Makino I, Hayashi H, Nakagawara H, Kitagawa H, Fushida S, Fujimura T, Saito H, Munesue S, Yamamoto Y, Ohta T. Sivelestat sodium hydrate inhibits neutrophil migration to the vessel wall and suppresses hepatic ischemia-reperfusion injury. Dig Dis Sci 2014; 59(4):787-94.
  8. Harada K, Kakuda Y, Sato Y, Ikeda H, Shimoda S, Yamamoto Y, Inoue H, Ohta H, Kasashima S, Kawashima A, Nakanuma Y. Alteration of energy metabolism in the pathogenesis of bile duct lesions in primary biliary cirrhosis. J Clin Pathol 2014; 67(5):396-402.
  9. Ullah MA, Loh Z, Gan WJ, Zhang V, Yang H, Li JH, Yamamoto Y, Schmidt AM, Armour CL, Hughes JM, Phipps S, Sukkar MB. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation. J Allergy Clin Immunol 2014; 134(2): 440-50.

2013

  1. Myat TTW, Yamamoto Y, Munesue S, Han D, Harada S, Yamamoto H. Validated liquid culture monitoring system for lifespan extension of Caenorhabditis elegans through genetic and dietary manipulations. Aging Dis 2013; 4(4):178-85.
  2. Akther S, Korshnova N, Zhong J, Liang M, Cherepanov SM, Lopatina O, Komleva YK, Salmina AB, Nishimura T, Fakhrul AAKM, Hirai H, Kato I, Yamamoto Y, Takasawa S, Okamoto H, Higashida H. CD38 in the nucleus accumbens and oxytocin are related to paternal behavior in mice. Mol Brain 2013; 6:41.
  3. Kim MS, Yamamoto Y, Kim K, Kamei N, Shimada T, Liu L, Moore K, Woo JR, Shoelson SE, Lee J. Regulation of diet-induced adipose tissue and systemic inflammation by salicylates and pioglitazone. PLoS ONE 2013; 8(12):e82847.
  4. Takeuchi A, Yamamoto Y, Munesue S, Harashima A, Shimizu K, Yonekura H, Yamamoto H, Tsuchiya H. Low molecular weight heparin inhibits RAGE-dependent human fibrosarcoma cell growth and metastasis. Cancer Sci 2013; 104(6):740-9.
  5. Takahashi HK, Sadamori H, Liu K, Wake H, Mori S, Yoshino T, Yamamoto Y, Yamamoto H, Nishibori M. Role of cell-cell interactions in HMGB1 cytokine activity in human PBMCs and mouse splenocytes. Eur J Pharmacol 2013; 701(1-3):194-202.
  6. Monden M, Koyama H, Otsuka Y, Morioka T, Mori K, Shoji T, Mima Y, Motoyama K, Fukumoto S, Shioi A, Emoto M, Yamamoto Y, Yamamoto H, Nishizawa Y, Kurajoh M, Yamamoto T, Inaba M. Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of toll-like receptor 2. Diabetes 2013; 62(2):478-89.
  7. Han D, Yamamoto Y, Munesue S, Motoyoshi S, Saito H, Myat TTW, Watanabe T, Tsuneyama K, Yamamoto H. Induction of RAGE by insufficient leptin action triggers pancreatic β-cell failure in type 2 diabetes. Genes Cells 2013; 18(4):302-14.
  8. Munesue S, Yamamoto Y, Urushihara R, Inomata K, Saito H, Motoyoshi S, Watanabe T, Yonekura H, Yamamoto H. Low-molecular weight fractions of Japanese soy sauce act as a RAGE antagonist via inhibition of RAGE trafficking to lipid rafts. Food Funct 2013; 4(12):1835-42.
  9. Abe T, Harashima A, Xia T, Konno H, Konno K, Morales A, Ahn J, Gutman D, Barber GN. STING recognition of cytoplasmic DNA instigates cellular defense. Mol Cell 2013;　50(1):5-15.

2012

  1. Kitade H, Sawamoto H, Nagashimada M, Inoue H, Yamamoto Y, Sai Y, Takamura T, Yamamoto H, Miyamoto K, Ginsberg HN, Mukaida N, Kaneko S, Ota T. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes 2012; 61(7):1680-90.
  2. Saito H, Yamamoto Y, Yamamoto H. Diabetes alters the subsets of mouse endothelial progenitor cells that reside in blood, bone marrow and spleen. Am J Physiol Cell Physiol 2012; 302(6):C892-901.
  3. Sugihara T, Munesue S, Yamamoto Y, Sakurai S, Akhter N, Kitamura Y, Shiba K, Watanabe T, Yonekura H, Hayashi Y, Hamada J, Yamamoto H. Endogenous secretory receptor for advanced glycation end-products inhibits amyloid-β1-42 uptake into mouse brain. J Alzheimer’s Dis 2012; 28(3):709-20.
  4. Kamide T, Kitao Y, Takeichi T, Okada A, Mohri H, Schmidt AM, Kawano T, Munesue S, Yamamoto Y, Yamamoto H, Hamada J, Hori O. RAGE mediates vascular injury and delayed neuronal death after global cerebral ischemia. Neurochem Int 2012; 60(3):220-8.
  5. Okuma Y, Liu K, Wake H, Zhang J, Maruo T, Date I, Yoshino T, Ohtsuka A, Otani N, Tomura S, Shima K, Yamamoto Y, Yamamoto H, Takahashi HK, Mori S, Nishibori M. Anti-HMGB1 monoclonal antibody ameliorates fluid percussion-induced brain injury in rats through protection of BBB and inhibition of inflammatory responses. Ann Neurol 2012; 72(3):373-84.

2011

  1. Yamamoto Y,　Harashima　A,　Saito　H,　Tsuneyama　K,　Munesue S, Han D, Watanabe T, Asano M, Takasawa S, Okamoto H, Shimura S, Karasawa T, Yonekura H, Yamamoto H. Septic shock is associated with receptor for advanced glycation endproducts (RAGE) ligation of LPS. J Immunol 2011; 186(5):3248-57.
  2. Takagi T, Taguchi O, D’Alessandro-Gabazza CN, Toda M, Kobayashi T, Boveda Ruiz, Gil Bernabe P, Aoki S, Chiba F, Yano Y, Conway EM, Munesue S, Yamamoto Y, Yamamoto H, Suzuki K, Takei Y, Morser Y, Esteban C.Gabazza. Inhibition of allergic bronchial asthma by thrombomodulin is mediated by dendritic cells. Am J Respir Crit Care Med 2011; 183(1):31-42.
  3. He M, Kubo H, Morimoto K, Fujino N, Suzuki T, Takahashi T, Yamada M, Yamaya M, Yamamoto Y, Yamamoto H. RAGE binds phosphatidylserine and mediates clearance of apoptotic cells. EMBO Rep 2011; 12(4):358-64.
  4. Riazy M, Chen JH, Yamamoto Y, Yamamoto H, Duronio V, Steinbrecher UP. OxLDL mediated survival of macrophages does not require LDL internalization or signaling by major pattern recognition receptors. Biochem Cell Biol 2011; 89(4):387-95.

2010

  1. Hamada Y, Kitazawa S, Kitazawa R, Kono K, Goto S, Komaba H, Fujii H, Yamamoto Y, Yamamoto H, Usami M, Fukagawa M. The effects of receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic condition. Endocrine 2010; 38(3):369-76.
  2. Ohe K, Watanabe T, Harada S, Munesue S, Yamamoto Y, Yonekura H, Yamamoto H. Regulation of alternative splicing of the receptor for advanced glycation endproducts (RAGE) through G-rich cis-elements and heterogenous nuclear ribonucleoprotein (hnRNP) H. J Biochem 2010; 147(5):651-9.
  3. Ilchmann A, Burgdorf S, Waibler Z, Nagai R, Wellner A, Yamamoto Y, Yamamoto H, Scheurer S, Henle T, Kurts C, Kalinke U, Vieths S, Toda M. Glycation of a food allergen by the Maillard reaction enhances its T-cell immunogenicity: the role of macrophage scavenger receptor class A type I and II. J Allergy Clin Immunol 2010; 125(1):175-83.
  4. Li J, Qu X, Yao J, Caruana G, Ricardo SD, Yamamoto Y, Yamamoto H, Bertram JF. Blockade of endothelial-mesenchymal-transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 2010; 59(10):2612-24.
  5. Harashima A, Guettouche T, Barber GN. Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase PKR constitutes a novel mechanism of translational regulation and cellular defense. Genes Dev 2010; 24(23):2640-53.

Before 2009

  1. Yamagishi S, Hsu CC, Taniguchi M, Harada S, Yamamoto Y, Ohsawa K, Kobayashi K, YamamotoH. Receptor-mediated toxicity to pericytes of advanced glycosylation end　products: a possible mechanism of pericyte loss in diabetic microangiopathy. Biochem Biophys Res Commun 1995; 213:681-7.
  2. Yamamoto Y, Yamagishi S, Hsu CC, Yamamoto H. Advanced glycation endproducts-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Biochem Biophys Res Commun 1996; 222:700-3.
  3. Yamagishi S, Yamamoto Y, Harada S, Hsu CC, Yamamoto H. Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett 1996; 384:103-6.
  4. Nagai Y, Ohsawa K, Ohta M, Hisada A, Yamashita H, Yoshizawa M, Yamamoto Y, Takamura T, Kobayashi K. Inhibitory effect of cyclosporin A on prolactin synthesis in GH3 cells. Tohoku J Exp Med 1996; 180:337-46.
  5. Yamamoto Y, Yamagishi S, Noto Y, Taniguchi M, Nagai Y, Ohsawa K, Kida H, Kobayashi K. The first case of insulin-dependent diabetes mellitus with prominent spurious hyperglucagonemia due to interference of immunoglobulin G in glucagon radioimmunoassay (OAL-123) system. Horm Res 1996; 45:295-9.
  6. Yamamoto Y, Noto Y, Saito M, Ichizen H, Kida H. Spinal cord compression by heterotopic ossification associated with Pseudohypoparathyroidism. J Int Med Res 1997; 25:364-8.
  7. Yamagishi S, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, Ooka H, Satozawa N, Kawakami T, Nomura M, Yamamoto H. Advanced glycation endproducts-driven angiogenesis in vitro: Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997; 272:8723-30.
  8. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998; 41:1435-41.
  9. Yonekura H, Sakurai S, Liu X, Migita H, Wang H, Yamagishi S, Nomura M, Abedin Md J, Unoki H, Yamamoto Y, Yamamoto H. Placenta growth factor and vascular endothelial growth factor B and C expressions in microvascular endothelial cells and pericytes: implication in autocrine and paracrine regulation of angiogenesis. J Biol Chem 1999; 274(49):35172-8.
  10. Yamagishi S, Kawakami T, Fujimori H, Yonekura H, Tanaka N, Yamamoto Y, Urayama H, Watanabe Y, Yamamoto H. Insulin stimulates the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. Microvasc Res 1999; 57:329-39.
  11. Yamagishi S, Yonekura H, Yamamoto Y, Fujimori H, Sakurai S, Tanaka N, Yamamoto H. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest 1999; 79:501-9.
  12. Kato I, Yamamoto Y, Fujimura M, Noguchi N, Takasawa S, Okamoto H. CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, [Ca2+]i, and insulin secretion. J Biol Chem 1999; 274(4):1869-72.
  13. Abedin MdJ, Yonekura H, Migita H, Karasawa J, Yamamoto Y, Yamamoto H. Molecular heterogeneity of the receptor for advanced glycation endproducts. J Biochem Mol Biol Biophys 2000; 4:373-81.
  14. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation endproducts is induced by the glycation products themselves and TNF-α through NF-KB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 275(33):25781-90.
  15. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108(2):261-8.
  16. Nakajima M, Kwon JT, Tanaka N, Zenda T, Yamamoto Y, Yamamoto H, Yamazaki H, Yamamoto T, Kuroiwa Y, Yokoi T. Relationship between interindividual differences in nicotine metabolism and CYR2A6 genetic polymorphism in humans. Clin Pharmcol Ther 2001; 68:72-8.
  17. Petrova RG, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, Takasawa S, Okamoto H, Imaizumi Y, Yamamoto H. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 2002; 34(10):1425-31.
  18. Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Petrova RG, Abedin MdJ, Li H, Yasui K, Takasawa S, Okamoto H, Yamamoto H. Novel splice variants of the receptor for advanced glycation endproducts (RAGE) expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370:1097-109.
  19. Miura J, Uchigata Y, Yamamoto Y, Takeuchi M, Sakurai S, Watanabe T, Yonekura H, Yamagishi S, Makita Z, Sato A, Omori Y, Yamamoto H, Iwamoto Y. AGE downregulation of monocyte expression of RAGE mRNA and its association with diabetic complications in type 1 diabetes. J Diabetes Complication 2004; 18:53-60.
  20. Ohashi S, Abe H, Takahashi T, Yamamoto Y, Takeuchi M, Arai H, Nagata K, Kita T, Okamoto H, Yamamoto H, Doi T. Advanced glycation end products increase collagen-specific chaperone protein in mouse diabetic nephropathy. J Biol Chem 2004; 279:19816-23.
  21. Li H, Yonekura H, Kim CH, Sakurai S, Yamamoto Y, Takiya T, Futo S, Watanabe T, Yamamoto H. Possible participation of pICln in the regulation of angiogenesis through alternative splicing of VEGF receptor mRNAs. Endothelium 2004; 11(5-6):293-300.
  22. Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Takano Y, Yamamoto H, Yamamoto Y*. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 2005; 18(10):1385-96. (*corresponding)
  23. Abeyama K, Stern MD, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, Yamamoto Y, Yamamoto H, Iino S, Taniguchi N, Murayama I. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115(5):1267-74.
  24. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji T, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanabe T, Yamamoto H, Nishizawa Y. Plasma level of endogenous secretory receptor for advanced glycation endproducts (esRAGE) is associated with components of the metabolic syndrome and atherosclerotic arterial wall thickness. Arterioscler Thromb Vasc Biol 2005; 25(12):2587-93.
  25. Harashima A, Yamamoto Y, Cheng C, Tsuneyama K, Myint KM, Takeuchi A, Yoshimura K, Li H, Watanabe T, Takasawa S, Okamoto H, Yonekura H, Yamamoto H. Identification of mouse ortholog of endogenous secretory receptor for advanced glycation endproducts: structure, function and expression. Biochem J 2006; 396(1):109-15.
  26. Inagi R, Yamamoto Y, Nangaku M, Usuda M, Okamato H, Kurokawa K, van Ypersele de Strihou C, Yamamoto H, Miyata T. A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in the RAGE/iNOS transgenic mice. Diabetes 2006; 55:356-66.
  27. Sakurai S, Yamamoto Y, Tamei H, Matsuki H, Obata H, Hui L, Miura J, Osawa M, Uchigata Y, Iwamoto Y, Watanabe T, Yonekura H, Yamamoto H. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 2006; 73:158-65.
  28. Myint KM, Yamamoto Y*, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Hashimoto N, Asano M, Takasawa S, Okamoto H, Yamamoto H. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low molecular weight heparin. Diabetes 2006; 55(9):2510-22. (*equally contributed)
  29. Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, Motoyama K, Mori K, Shioi A, Yamamoto Y, Yamamoto H, Nishizawa Y. Receptor for advanced glycation endproducts is involved in impaired angiogenic response in diabetes. Diabetes 2006; 55(8):2245-55.
  30. Nakajima M, Itoh M, Yamanaka H, Fukami T, Tokudome S, Yamamoto Y, Yamamoto H, Yokoi T. Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6. J Clin Pharmacol 2006; 46(3):337-44.
  31. Kobayashi S, Kubo H, Suzuki T, Ishizawa K, Yamada M, He M, Yamamoto Y, Yamamoto H, Sasano H, Sasaki H, Suzuki S. Endogenous secretory receptor for advanced glycation end products in non-small cell lung carcinoma. Am J Respir Crit Care Med 2007; 175(2):184-9.
  32. Miura J, Yamamoto Y, Osawa M, Watanabe T, Yonekura H, Uchigata Y, Yamamoto H, Iwamoto Y. Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler Thromb Vasc Biol 2007; 27(1):253-4.
  33. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TCB, Moore J, Yamamoto Y, Yamamoto H, Adamis AP. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthal Vis Sci 2007; 48(2):858-65.
  34. Yamamoto Y, Yonekura H, Watanabe T, Sakurai S, Li H, Harashima A, Myint KM, Osawa M, Takeuchi A, Takeuchi M, Yamamoto H. Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract 2007; 1:s30-40.
  35. Takeuchi A, Yamamoto Y, Tsuneyama K, Cheng C, Yonekura H, Watanabe T, Shimizu K, Tomita K, Yamamoto H, Tsuchiya H. Endogenous secretory receptor for advanced glycation end-products as a novel prognostic marker in chondrosarcoma. Cancer 2007; 109(12):2532-40.
  36. He M, Kubo H, Ishizawa K, Hegab AE, Yamamoto Y, Yamamoto H, Yamaya M. The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 293(6):L1427-36.
  37. Osawa M, Yamamoto Y*, Sakurai S, Watanabe T, Yonekura H, Uchigata Y, Iwamoto Y, Yamamoto H. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. Biochem Biophy Acta 2007; 1770(10):1468-74. (*corresponding)
  38. Nozaki I, Watanabe T, Kawaguchi M, Akatsu H, Tsuneyama K, Yamamoto Y, Ohe K, Yonekura H, Yamada M, Yamamoto H. Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer’s disease brains. Arch Histol Cytol 2007; 70(5):279-90.
  39. Sakatani S, Seto-Ohshima A, Shinohara Y, Yamamoto Y, Yamamoto H, Itohara S, Hirose H. Neural activity dependent release of S100B from astrocytes enhances kainite-induced gamma oscillations in vivo. J Neurosci 2008; 28(43):10928-36.
  40. Matsumoto S, Yoshida T, Murata H, Harada S, Fujita N, Nakamura S, Yamamoto Y, Watanabe T, Yonekura H, Yamamoto H, Ohkubo T, Kobayashi Y. The solution structure of variable-type domain of receptor for advanced glycation endproducts: a new insight into AGE-RAGE interaction. Biochemistry 2008; 47(47):12299-311.
  41. Sun L, Ishida T, Yasuda T, Kojima Y, Honjo T, Yamamoto Y, Yamamoto H, Ishibashi S, Hirata K, Hayashi Y. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res 2009; 82(2):371-81.
  42. Sakatani S, Yamada K, Homma C, Munesue S, Yamamoto Y, Yamamoto H, Hirase H. Deletion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice. PLoS ONE 2009; 4(12):e8309.
  43. Mi QS, Yan SL, Wang ZZ, Ding KH, Li C, Wang L, Zhou L, Yamamoto Y, Yamamoto H, Okamoto H, Isales C. Spontaneous bone loss in RIP-iNOS transgenic mouse: A mouse model for diabetes- mediated osteopenia/osteoporosis. Cell Cycle 2009; 8(24):4179-81.
back top